Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: A meta-analysis

Schizophrenia Bulletin

Volumn 36, Issue 4, 2010, Pages 723-731

  Koning, Jeroen P F ^b   Tenback, Diederik E ^a,c   Van Os, Jim ^d,e   Aleman, André ^f,g   Kahn, René S ^b,c   Van Harten, Peter N ^a,g  

^a Symfora Groep   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f BCN Neuroimaging Center   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Family; Movement disorders; Nonaffective psychosis; Spontaneous; Vulnerability

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSKINESIA; HUMAN; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SYSTEMATIC REVIEW; COMORBIDITY; CORPUS STRIATUM; GENETIC PREDISPOSITION; GENETICS; NERVE TRACT; PATHOPHYSIOLOGY; REFERENCE VALUE; RISK; SUBSTANTIA NIGRA;

COMORBIDITY; CORPUS STRIATUM; DYSKINESIAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURAL PATHWAYS; ODDS RATIO; PARKINSONIAN DISORDERS; REFERENCE VALUES; RISK; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

EID: 77958171680     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn146     Document Type: Article

References (78)

1. Kane JM, Smith JM. Tardive dyskinesia: prevalence and riskfactors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Weiden P. Neuroleptic-induced parkinsonism. Vol DSM-IVSource Book 1. Washington, DC: American Psychiatric Association(APA); 1994.
4. Bleuler E. Dementia Praecox or the Group of Schizophrenia.New York, NY: International University Press; 1950.
5. Kraepelin E. Dementia Praecox and Paraphrenia. New York, NY: Robert E Krieger; 1919.
6. Reiter P. Extrapyramidal motor-disturbances in dementiapraecox. Acta Psychiatr Neurol Scand. 1926;1:287-309.
7. Caligiuri MP, Lohr JB. A disturbance in the control of muscleforce in neuroleptic-naïve schizophrenic patients. Biol Psychiatry.1994;35:104-111.
8. Caligiuri MP, Lohr JB, Jeste DV. Parkinsonism in neurolepticnaiveschizophrenic patients. Am J Psychiatry. 1993;150:1343-8.
9. Chatterjee A, Chakos M, Koreen A, et al. Prevalence andclinical correlates of extrapyramidal signs and spontaneousdyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 1995;152:1724-1729.
10. Chong SA, Subramaniam M, Verma S. Spontaneous parkinsonismin antipsychotic-naïve patients with first-episodepsychosis. Can J Psychiatry. 2005;50:429-431.
11. Chorfi M, Moussaoui D. Lack of dyskinesias in unmedicatedschizophrenics. Psychopharmacology. 1989;97:423.
12. Cortese L, Caligiuri MP, Malla AK, et al. Relationship of neuromotor disturbances to psychosis symptoms in firstepisodeneuroleptic-naïve schizophrenia patients. Schizophr Res. 2005;75:65-75.
13. Fenn DS, Moussaoui D, Hoffman WF, et al. Movements innever-medicated schizophrenics: a preliminary study. Psychopharmacology.1996;123:206-210.
14. Gervin M, Browne S, Lane A, et al. Spontaneous abnormalinvoluntary movements in first-episode schizophrenia andschizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry.1998;155:1202-1206.
15. Hoffman W, Kadri N, Fenn D. Choreo-athetoid movementsoccur spontaneously in never-medicated patients with schizophrenia.Eur Neuropsychopharmacol. 1996;11(suppl 4):170s.
16. Honer WG, Kopala LC, Rabinowitz J. Extrapyramidalsymptoms and signs in first-episode, antipsychotic exposedand non-exposed patients with schizophrenia or relatedpsychotic illness. J Psychopharmacol. 2005;19:277-285.
17. Kopala LC, Good KP, Honer WG. Extrapyramidal signs andclinical symptoms in first-episode schizophrenia: response tolow-dose risperidone. J Clin Psychopharmacol. 1997;17:308-313.
18. McCreadie RG, Barron ET, Winslow GS. The NithsdaleSchizophrenia Survey: II. Abnormal movements. Br J Psychiatry.1982;140:587-590.
19. McCreadie RG, Latha S, Thara R, Padmavathi R, AyankaranJR. Poor memory, negative symptoms and abnormal movementsin never-treated Indian patients with schizophrenia.Br J Psychiatry. 1997;171:360-363.
20. McCreadie RG, Ohaeri JU. Movement disorder in never andminimally treated Nigerian schizophrenic patients. Br J Psychiatry. 1994;164:184-189.
21. McCreadie RG, Thara R, Kamath S, et al. Abnormal movementsin never-medicated Indian patients with schizophrenia.Br J Psychiatry. 1996;168:221-226.
22. McCreadie RG, Thara R, Padmavati R, Srinivasan TN, Jaipurkar SD. Structural brain differences between nevertreatedpatients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonanceimaging study. Arch Gen Psychiatry. 2002;59:332-336.
23. McCreadie RG, Padmavati R, Thara R, Srinivasan TN.Spontaneous dyskinesia and parkinsonism in nevermedicated, chronically ill patients with schizophrenia:18-month follow-up. Br J Psychiatry. 2002;181:135-137.
24. Moussaoui D, Fenn D, Kadri N. Comparative studies of abnormalinvoluntary movements in never-treated vs. treatedpopulations with schizophrenia. Eur Psychiatry.1996;11(suppl 4):170s.
25. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntarydisordersofmovement:theirprevalence, severity, anddistributionin chronic schizophrenics with and without treatmentwith neuroleptics. Arch Gen Psychiatry. 1982;39:452-461.
26. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF. Differentiatingprimary from secondary negative symptoms inschizophrenia: a study of neuroleptic-naïve patients beforeand after treatment. Am J Psychiatry. 2000;157:1461-1466.
27. Puri BK, Barnes TR, Chapman MJ, Hutton SB, Joyce EM.Spontaneous dyskinesia in first episode schizophrenia.J Neurol Neurosurg Psychiatry. 1999;66:76-78.
28. Silva I, Jerez C, Ruiz T, et al. Ausencia de movimientos involuntariosanormales en esquinzofrenicos nunca tratados. Actas Luso-Esp Neurol Psiquiatr. 1994;66:200-202.
29. Appels MC, Sitskoorn MM, de Boo M, et al. Neurologicalsigns in parents of schizophrenic patients. Neuroreport.2002;13:575-579.
30. Chen YL, Chen YH, Mak FL. Soft neurological signs inschizophrenic patients and their nonpsychotic siblings.J Nerv Ment Dis. 2000;188:84-89.
31. Egan MF, Hyde TM, Bonomo JB, et al. Relative risk of neurological signs in siblings of patients with schizophrenia.Am J Psychiatry. 2001;158:1827-1834.
32. Flyckt L, Sydow O, Bjerkenstedt L, et al. Neurological signsand psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res.1999;86:113-129.
33. Ismail B, Cantor-Graae E, McNeil TF. Neurological abnormalitiesin schizophrenic patients and their siblings. Am J Psychiatry. 1998;155:84-89. (Pubitemid 28037553)
34. Kinney DK, Woods BT, Yurgelun-Todd D. Neurologic abnormalitiesin schizophrenic patients and their families. II.Neurologic and psychiatric findings in relatives. Arch Gen Psychiatry. 1986;43:665-668.
35. Kinney DK, Yurgelun-Todd DA, Woods BT. Hard neurologicsigns and psychopathology in relatives of schizophrenicpatients. Psychiatry Res. 1991;39:45-53.
36. Tarbox SI, Pogue-Geile MF. Spontaneous dyskinesia andfamilial liability to schizophrenia. Schizophr Res. 2006;81:125-137.
37. Gupta S, Andreasen NC, Arndt S, et al. Neurological softsigns in neuroleptic-naïve and neuroleptic-treated schizophrenicpatients and in normal comparison subjects. Am J Psychiatry. 1995;152:191-196.
38. Sanders RD, Keshavan MS, Schooler NR. Neurological examinationabnormalities in neuroleptic-naïve patients withfirst-break schizophrenia: preliminary results. Am J Psychiatry.1994;151:1231-1233.
39. Erlenmeyer-Kimling L, Golden RR, Cornblatt BA. A taxometricanalysis of cognitive andneuromotor variables in childrenat risk for schizophrenia. J Abnorm Psychol. 1989;98:203-208.
40. Fish B, Marcus J, Hans SL, Auerbach JG, Perdue S. Infantsat risk for schizophrenia: sequelae of a genetic neurointegrativedefect. A review and replication analysis of pandysmaturationin the Jerusalem Infant Development Study. Arch Gen Psychiatry. 1992;49:221-235.
41. Lencer R, Eismann G, Kasten M, et al. Family history of primarymovementdisorders as a predictor for neuroleptic-inducedextrapyramidal symptoms. Br J Psychiatry. 2004;185:465-471.
42. Marcus J, Hans SL, Auerbach JG, Auerbach AG. Children atrisk for schizophrenia: the Jerusalem Infant DevelopmentStudy. II. Neurobehavioral deficits at school age. Arch Gen Psychiatry. 1993;50:797-809.
43. Marcus J, Hans SL, Lewow E, Wilkinson L, Burack CM.Neurological findings in high-risk children: childhoodassessment and 5-year followup. Schizophr Bull. 1985;11:85-100.
44. Marcus J, Hans SL, Mednick SA, Schulsinger F, MichelsenN. Neurological dysfunctioning in of fspring of schizophrenicsin Israel and Denmark. A replication analysis. Arch Gen Psychiatry.1985;42:753-761.
45. Rieder RO, Nichols PL. of fspring of schizophrenics. III. Hyperactivityand neurological soft signs. Arch Gen Psychiatry.1979;36:665-674.
46. Rossi A, De Cataldo S, Di Michele V, et al. Neurological softsigns in schizophrenia. Br J Psychiatry. 1990;157:735-739.
47. Schiffman J, Walker E, Ekstrom M, et al. Childhood videotapedsocial and neuromotor precursors of schizophrenia:a prospective investigation. Am J Psychiatry. 2004;161:2021-2027.
48. Yazici AH, Demir B, Yazici KM, Gogus A. Neurological softsigns in schizophrenic patients and their nonpsychotic siblings.Schizophr Res. 2002;58:241-246.
49. Guy E. Abnormal Involuntary Movement Scale, ECDEUassessment manual for psychopharmacology. Rockville, MD:U.S. Dept. of Health, Education, and Welfare, Public HealthService, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, PsychopharmacologyResearch Branch, Division of Extramural ResearchPrograms; 1976.
50. Chouinard G, Chouinard-Ross A, Annable L, Jones B.The extrapyramidal rating scale. Can J Neurol Sci. 1980;7:233.
51. Simpson GM, Angus JW. A rating scale for extrapyramidalside effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
52. Glazer WM. Review of incidence studies of tardive dyskinesiaassociated with typical antipsychotics. J Clin Psychiatry.2000;61(suppl 4):15-20.
53. Fleiss JL. The statistical basis of meta-analysis. Stat MethodsMed Res. 1993;2:121-145.
54. Lipsey MW, Wilson DB. The way in which interventionstudies have ''personality'' and why it is important to metaanalysis.Eval Health Prof. 2001;24:236-254.
55. Hasselblad V, Hedges LV. Meta-analysis of screening anddiagnostic tests. Psychol Bull. 1995;117:167-178.
56. Ismail B, Cantor-Graae E, McNeil TF. Neurodevelopmentalorigins of tardivelike dyskinesia in schizophrenia patients andtheir siblings. Schizophr Bull. 2001;27:629-641.
57. Kaufmann D. Clinical Neurology for Psychiatrists. 5th ed.Philidelphia, Pa: Saunder Company, WB; 2001.
58. Cohen J. Statistical Power Analysis for Behavioral Sciences.New Jersey, NJ: Lawrence Erlbaum Associates; 1988.
59. Whitlock MC. Combining probability from independenttests: the weighted Z-method is superior to Fisher's approach.J Evol Biol. 2005;18:1368-1373.
60. Orwin R. A fail-safe N for effect size in meta-analysis. J Educstat. 1983;8:157-159.
61. Wolff AL, O'Driscoll GA. Motor deficits and schizophrenia:the evidence from neuroleptic-naïve patients and populationsat risk. J Psychiatr Neurosci. 1999;24:304-314.
62. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia.J Clin Psychiatry. 2000;61(suppl 4):10-14.
63. Torrey EF. Studies of individuals with schizophrenia nevertreated with antipsychotic medications: a review. Schizophr Res. 2002;58:101-115.
64. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopaminefunction in striatum of neuroleptic-naïve schizophrenicpatients. Lancet. 1995;346:1130-1131.
65. Laruelle M. Dopamine transmission in the schizophrenicbrain. In: Hirsch S, Weinberger D, eds. Schizophrenia. PartTwo, Biological Aspects. 1st ed. Oxford, UK: Blackwell Publishing;2003:365-387.
66. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopaminesynthesis in first-degree relatives of patients with schizophrenia.Biol Psychiatry. 2008;63:114-117.
67. Mittal VA, Neumann C, Saczawa M, Walker EF. Longitudinalprogression of movement abnormalities in relation to psychoticsymptoms in adolescents at high risk of schizophrenia.Arch Gen Psychiatry. 2008;65:165-171.
68. Mittal VA, Walker EF. Movement abnormalities predict conversionto Axis I psychosis among prodromal adolescents.J Abnorm Psychol. 2007;116:796-803.
69. Walker EF. Developmentally moderated expressions of theneuropathology underlying schizophrenia. Schizophr Bull.1994;20:453-480.
70. Boks MP, Russo S, Knegtering R, van den Bosch RJ. Thespecificity of neurological signs in schizophrenia: a review.Schizophr Res. 2000;43:109-116.
71. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophreniapopulation. BMC Neurol. 2005;5:5.
72. Schooler NR, Kane JM. Research diagnoses for tardivedyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
73. Dean CE, Russell JM, Kuskowski MA, Caligiuri MP, NugentSM. Clinical rating scales and instruments: how do they comparein assessing abnormal, involuntary movements? J Clin Psychopharmacol. 2004;24:298-304.
74. Andreasen NC, Carpenter WT, Jr. Diagnosis and classificationof schizophrenia. Schizophr Bull. 1993;19:199-214.
75. McCormick LM, Flaum M. Diagnosing schizophrenia circa2005: how and why? Curr Psychiatry Rep. 2005;7:311-315.
76. MurrayRM, Van Os J. Predictors of outcome in schizophrenia.J Clin Psychopharmacol. 1998;18(suppl 1):2S-4S.
77. Schroder J, Silvestri S, Bubeck B, et al. D2 dopamine receptorup-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a followupstudy with 123I-iodobenzamide single photon emissioncomputed tomography in the drug-naïve state and afterneuroleptic treatment. Biol Psychiatry. 1998;43:660-665.
78. Gottesman II, Gould TD. The endophenotype concept in psychiatry:etymology and strategic intentions. Am J Psychiatry.2003;160:636-645.